Search results for " cholesterol"

showing 10 items of 243 documents

LIPID PARAMETERS AND LEFT VENTRICULAR MASS IN ESSENTIAL HYPERTENSIVE PATIENTS

2014

arterila hypertensionlipidHDL cholesterolechocardiographyhypertensive heart disease
researchProduct

Lecithin-cholesterol-acyltransferase deficiency: autosomal recessive transmission in a large kindred.

2008

Thirty-four members of a single Sardinian kindred with lecithin-cholesterol-acyltransferase deficiency have been studied. The kindred spans four generations and the parents of the two affected siblings are blood relatives. Segregation of the acyltransferase deficiency gene in the family clearly demonstrated an autosomal recessive mode of inheritance. Thirteen family members, including all obligate heterozygotes, had roughly half-normal acyltransferase activities (mean +/- S.D. = 0.39 +/- 0.06 mU/ml) when compared to 17 intrafamilial controls and spouses (mean +/- S.D. = 0.72 +/- 0.09 mU/ml) and 40 blood donors from Marburg/Lahn (mean +/- S.D. =0.76 +/- 0.1 mU/ml). Characterization of the he…

Plasma lipoproteinMaleHeterozygoteThalassemiaLipoproteinsGenes RecessiveConsanguinityConsanguinityLecithin Cholesterol Acyltransferase DeficiencyGeneticsmedicineHumansGenetics (clinical)GeneticsLecithin cholesterol acyltransferase deficiencybiologyHeterozygote advantagemedicine.diseaseHypolipoproteinemiasPedigreeAcyltransferaseLecithin—cholesterol acyltransferasebiology.proteinThalassemiaFemaleHypolipoproteinemiaClinical genetics
researchProduct

The lipid-lowering effects of lomitapide are unaffected by adjunctive apheresis in patients with homozygous familial hypercholesterolaemia – A post-h…

2015

AbstractObjectiveLomitapide (a microsomal triglyceride transfer protein inhibitor) is an adjunctive treatment for homozygous familial hypercholesterolaemia (HoFH), a rare genetic condition characterised by elevated low-density lipoprotein-cholesterol (LDL-C), and premature, severe, accelerated atherosclerosis. Standard of care for HoFH includes lipid-lowering drugs and lipoprotein apheresis. We conducted a post-hoc analysis using data from a Phase 3 study to assess whether concomitant apheresis affected the lipid-lowering efficacy of lomitapide.MethodsExisting lipid-lowering therapy, including apheresis, was to remain stable from Week −6 to Week 26. Lomitapide dose was escalated on the basi…

MaleTime FactorsSettore MED/09 - Medicina InternaGastroenterologyMicrosomal triglyceride transfer proteinchemistry.chemical_compoundLipoprotein apheresisMedicineHyperlipoproteinemia Type IIHomozygous familial hypercholesterolaemia; Lipoprotein apheresis; Lomitapide; Adult; Anticholesteremic Agents; Benzimidazoles; Biomarkers; Blood Component Removal; Cholesterol LDL; Combined Modality Therapy; Female; Genetic Predisposition to Disease; Humans; Hyperlipoproteinemia Type II; Lipoprotein(a); Male; Phenotype; Time Factors; Treatment Outcome; Young Adult; Homozygote; Cardiology and Cardiovascular MedicinebiologyAnticholesteremic AgentsHomozygoteLipoprotein(a)Combined Modality TherapyCholesterolPhenotypeTreatment OutcomeBlood Component Removallipids (amino acids peptides and proteins)FemaleCardiology and Cardiovascular MedicineAdultmedicine.medical_specialtySocio-culturaleLipoprotein apheresiArticleLDLHyperlipoproteinemia Type IIYoung AdultHomozygous familial hypercholesterolaemiaInternal medicinePost-hoc analysisHumansGenetic Predisposition to DiseaseHomozygous familial hypercholesterolaemia; Lipoprotein apheresis; Lomitapide; Cardiology and Cardiovascular Medicinebusiness.industryCholesterol LDLLomitapideLomitapideEndocrinologyApheresischemistryConcomitantAdjunctive treatmentbiology.proteinBenzimidazolesbusinessBiomarkersLipoprotein(a)Atherosclerosis
researchProduct

Prevalence Of familial hypercholeSTerolaemia (FH) in Italian Patients with coronary artERy disease: The POSTER study

2020

Background and aims: Familial hypercholesterolaemia (FH) is a powerful risk factor for cardiovascular (CV) events. High levels of low-density lipoprotein cholesterol (LDL-C) since birth are linked to the early onset of atherosclerotic disease. A genetic mutation determining FH is present in about one subject out of 250; FH should be more represented among subjects with a documented diagnosis of coronary artery disease (CAD). The POSTER Study evaluated the prevalence of FH in Italian patients with a recent CAD event. Methods: Eighty-two cardiology centres enrolled patients with a documented CAD event; CV risk profile, drug therapy and biochemical parameters were collected. Dutch Lipid Clinic…

Male0301 basic medicineAcute coronary syndromemedicine.medical_specialtySettore MED/09 - Medicina InternaFamilial hypercholesterolemiaFamilial hypercholesterolemia030204 cardiovascular system & hematologyCoronary revascularizationCoronary artery diseaseHyperlipoproteinemia Type IICoronary artery disease03 medical and health sciences0302 clinical medicinePharmacotherapyRisk FactorsInternal medicinePrevalencemedicineHumansLow-density lipoprotein cholesterolMyocardial infarctionRisk factorAgedHigh prevalencebusiness.industryCholesterol LDLMiddle Agedmedicine.diseaseCoronary revascularizationMyocardial infarction030104 developmental biologyItalyDutch lipid clinic networkCardiology and Cardiovascular MedicinebusinessAtherosclerosis
researchProduct

An Update on the Role of the Quality of LDL in Cardiovascular Risk:The Contribution of the Universities of Palermo and Zurich

2007

Low density lipoproteins (LDL) size seems to be an important predictor of cardiovascular events and progression of coronary artery disease and the predominance of small dense LDL have been accepted as an emerging cardiovascular risk factor by the National Cholesterol Education Program Adult Treatment Panel III. We recently showed increased LDL size or higher levels of small, dense LDL in different categories of patients at higher cardiovascular risk, such as those with coronary (including acute myocardial infarction) and non-coronary (including carotid disease, abdominal aortic aneurysm and peripheral arterial disease) forms of atherosclerosis or metabolic diseases (including type-II diabet…

medicine.medical_specialtyStatinUniversitiesmedicine.drug_classCoronary artery diseaseEzetimibeInternal medicineDrug DiscoverymedicineHumansPharmacology (medical)RosuvastatinCholesterol absorption inhibitorParticle SizeRisk factorNational Cholesterol Education Programbusiness.industrymedicine.diseasePolycystic ovaryLipoproteins LDLItalyCardiovascular DiseasesCardiologylipids (amino acids peptides and proteins)Cardiology and Cardiovascular MedicinebusinessSwitzerlandmedicine.drugRecent Patents on Cardiovascular Drug Discovery
researchProduct

Rapid degradation of ABCA1 protein following cAMP withdrawal and treatment with PKA inhibitor suggests ABCA1 is a short-lived protein primarily regul…

2020

Objectives: ATP-binding cassette transporter A1 (ABCA1) is a key player in the reverse cholesterol transport (RCT) and HDL biogenesis. Since RCT is compromised as a result of ABCA1 dysfunction in diabetic state, the objective of this study was to investigate the regulation of ABCA1 in a stably transfected 293 cells expressing ABCA1 under the control of cAMP response element. Methods: To delineate transcriptional and posttranscriptional regulation of ABCA1, 293 cells were stably transfected with the full length ABCA1 cDNA under the control of CMV promoter harboring cAMP response element. cAMP-mediated regulation of ABCA1 and cholesterol efflux were studied in the presence of 8-Br-cAMP and af…

0301 basic medicineEndocrinology Diabetes and MetabolismResponse elementABCA1030209 endocrinology & metabolismDiabeteProtein kinase03 medical and health sciences0302 clinical medicinecAMPpolycyclic compoundsInternal MedicineABCA1 GeneMedicinecardiovascular diseasesProtein kinase Abiologybusiness.industryReverse cholesterol transportHEK 293 cellsnutritional and metabolic diseaseshemic and immune systemsTransfectionCell biology030104 developmental biologyCell cultureABCA1biology.proteinlipids (amino acids peptides and proteins)Stably transfectedbusinessRegulationResearch ArticleJournal of Diabetes & Metabolic Disorders
researchProduct

Prevalence and determinants of diabetes mellitus in a representative sample of Italian adults

2022

PREVALENCE AND DETERMINANTS OF DIABETES MELLITUS IN A REPRESENTATIVE SAMPLE OF ITALIAN ADULTSBackground: Diabetes mellitus is a dramatic epidemic worldwide. This study providea an updated estimate of itsprevalence and determinants among Italian adults.Methods: Data were derived from a face-to-face survey conducted in 2013 on 2901 individuals (1391 men, 1510 women) aged ≥18 years, representative of the general adult Italian population. Odds ratios (OR) for diabetes versus non diabetes in relation to selected risk factors were derived using multiple logistic regression models.Results: Overall, 135 out of 2901 adults (4.7%) reported a diagnosis of diabetes, with similar prevalence in men (4.8%…

Pediatricsmedicine.medical_specialtyAspirinlcsh:R5-920diabetesbusiness.industrylcsh:Public aspects of medicineprevalenceRisk behaviorEpidemiology; prevention; diabeteslcsh:RA1-1270Odds ratioLogistic regressionmedicine.diseaseHigh cholesterolNever smokersItalyDiabetes mellitusPreventive interventionmedicinerisk factorssurveybusinesslcsh:Medicine (General)medicine.drugEpidemiology Biostatistics and Public Health
researchProduct

Pro-oxidant effects of 7-hydroperoxycholest-5-en-3β-ol on the copper-initiated oxidation of low density lipoprotein

1995

AbstractIn low density lipoproteins (LDL) supplemented with aged cholesterol and oxidized in the presence of Cu2+, an increase of the lipid oxidation parameters was observed compared with pure cholesterol-enriched LDL. A compound, identified as 7-hydroperoxycholesterol (7HPC), isolated from aged cholesterol and added to LDL, reproduced the above effects. The results indicate that the pro-oxidant effect of 7HPC is dependent on the hydroperoxy group since the corresponding alcohol derivative, 7α-hydroxycholesterol, had no such effect. These data suggest that among the LDL-associated lipid peroxides, cholesterol peroxides may have important implications in the susceptibility of this lipoprotei…

Oxidized LDLLipid PeroxidesVery low-density lipoproteinTime FactorsOxysterolBiophysicsBiochemistryMedicinal chemistrychemistry.chemical_compoundOxysterolLipid oxidationStructural BiologyOxidationGeneticsHumansMolecular BiologyIntermediate-density lipoproteinCholesterolCell BiologyOxidantsPro-oxidantLipoproteins LDLCholesterolchemistryLow-density lipoproteinCholesterol hydroperoxidelipids (amino acids peptides and proteins)Oxidation-ReductionAged cholesterolCopperLipoproteinFEBS Letters
researchProduct

Emergence of ovulatory cycles with aging in women with polycystic ovary syndrome (PCOS) alters the trajectory of cardiovascular and metabolic risk fa…

2013

Abstract STUDY QUESTION: What alters cardiovascular and metabolic risk factors with aging in women with polycystic ovary syndrome (PCOS)? SUMMARY ANSWER: Lipid parameters, mainly low-density lipoprotein (LDL) cholesterol, increase with aging, but not in women who attain ovulatory cycles. WHAT IS KNOWN ALREADY: Cardiovascular and metabolic parameters tend to increase with aging, but this has not been shown in a prospective longitudinal study in women with PCOS. Correlates of these changes have not been identified. STUDY DESIGN: A prospective cohort of 118 hyperandrogenic women with PCOS who were followed from the age of 20-25 years at 5 year intervals for 20 years. PARTICIPANTS/MATERIALS, SE…

AdultBlood GlucoseOvulationmedicine.medical_specialtyWaistSettore MED/09 - Medicina Internamedia_common.quotation_subjectmedicine.medical_treatmentBiologyBody Mass IndexSettore MED/13 - EndocrinologiaRisk FactorsInternal medicineTotal cholesterolPrevalencemedicineHumansInsulinLongitudinal StudiesGonadal Steroid HormonesOvulationmedia_commonMetabolic SyndromeCompeting interestsInsulinPolycystic ovary syndrome (PCOS)RehabilitationMetabolic riskAge Factorsnutritional and metabolic diseasesObstetrics and Gynecologymedicine.diseaseLipidsSettore MED/11 - Malattie Dell'Apparato CardiovascolareEndocrinologyReproductive MedicineCardiovascular DiseasesPCOS Cardiovascular risk aging hyperandrogenism ovarian function lipid alterationsFemalelipids (amino acids peptides and proteins)Waist CircumferenceMetabolic syndromePolycystic Ovary Syndrome
researchProduct

Nutraceuticals and functional foods for the control of plasma cholesterol levels. An intersociety position paper

2018

Current evidence shows that cholesterol management either reduces the likelihood of cardiovascular disease (CVD) or slows down its progression. Hence, it is important that all health professionals make appropriate use of all the available intervention strategies to control risk factors: from dietary improvement and positive lifestyle changes to the use of functional foods, food supplements, and drugs. This review examines the effect of the most frequently occurring cholesterol-lowering substances in functional foods or in supplements across Europe, namely plant sterols and stanols, monacolin K found in red yeast rice, berberine and beta-glucans. We conclude that currently available suppleme…

ConsensusFunctional foodsClinical Decision-MakingFood supplementDisease030204 cardiovascular system & hematologyLDL03 medical and health scienceschemistry.chemical_compound0302 clinical medicineNutraceuticalPlasma cholesterolRisk FactorsEnvironmental healthFood supplementsRed yeast riceMedicineAnimalsHumans030212 general & internal medicineCardiovascular risk; Cholesterol; Food supplements; Functional foods; LDL cholesterol; Primary prevention; Animals; Biomarkers; Cardiovascular Diseases; Cholesterol LDL; Clinical Decision-Making; Consensus; Dyslipidemias; Evidence-Based Medicine; Humans; Protective Factors; Risk Factors; Diet Healthy; Dietary Supplements; Functional Food; Risk Reduction BehaviorDyslipidemiasPharmacologyLdl cholesterolHealthyEvidence-Based MedicinePrimary preventionCholesterolbusiness.industryFunctional foodFood supplementation functional foods cholesterol LDL-cholesterol cardiovascular risk primary preventionCholesterol LDLProtective FactorsCardiovascular riskDietCardiovascular risk; Cholesterol; Food supplements; Functional foods; LDL cholesterol; Primary prevention; PharmacologyYoung ageCholesterolchemistryCardiovascular DiseasesDietary SupplementsLDL cholesterolPosition paperDiet HealthybusinessRisk Reduction BehaviorBiomarkers
researchProduct